Outpatient deep vein thrombosis treatment models

Pharmacotherapy

Volumn 18, Issue 6 III, 1998, Pages

  Leong, Wendy A ^a,b  

^a Burnaby Hospital   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARDEPARIN; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; TINZAPARIN;

AMBULATORY CARE; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG SAFETY; FOLLOW UP; HEALTH ECONOMICS; HEALTH PROGRAM; HEALTH SERVICE; HOSPITALIZATION; HUMAN; OUTPATIENT CARE; PRACTICE GUIDELINE;

AMBULATORY CARE; ANTICOAGULANTS; CANADA; EMERGENCY MEDICAL SERVICES; HUMANS; SELF MEDICATION; VENOUS THROMBOSIS;

EID: 0031796120     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (18)

1. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992;326:975-82.
2. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334: 677-81.
3. Koopman MMW, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996;334:682-7.
4. Hull RD, Raskob GE, Rosenbloom D, et al. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin versus intravenous heparin. Arch Intern Med 1997;157:289-94.
5. Leong WA, Fareed J. Unfractionated intravenous heparin may be replaced by low-molecular-weight heparin for most indications. Int Angiol 1997;16(suppl 1-3):92.
6. Cotran RS, Kumar V, Robbins SL. Fluid and hemodynamic derangements. In: Cotran RS, Kumar V, Robbins SL, eds. Robbins' pathologic basis of disease, 4th ed. Philadelphia: WB Saunders, 1989:99-101.
7. Ginsberg JS. Management of venous thromboembolism. N Engl J Med 1996;335:1816-28.
8. Hyers TM, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest 1995;108(suppl): 3355-51.
9. Claggett GP, Anderson FA, Heit J, et al. Prevention of venous thromboembolism. Chest 1995;108(suppl):312S-34.
10. Haeger K. Problems of acute deep vein thrombosis. The interpretation of signs or symptoms. Angiology 1969;20: 219-23.
11. Cranley JJ, Canos AJ, Sull WJ. The diagnosis of deep vein thrombosis: fallibility of clinical symptoms and signs. Arch Surg 1976;111:34-6.
12. Haines ST, Bussey HI. Diagnosis of deep vein thrombosis. Am J Health-Syst Pharm 1997;54:66-74.
13. Morrell MT, Dunnill MS. The post-mortem incidence of pulmonary embolism in a hospital population. Br J Surg 1968;55(5):347-52.
14. Leong WA, Siu A, Sparling TG. Evaluation of venous thromboembolism prophylaxis in high risk patients at a primary and secondary care centre. In: Balas P, ed. International congress of phlebology. Bologna, Italy: Monduzzi Editore, 1996:303-7.
15. Leong WA, Sui A, Sparling TG. Evaluation of DVT and pulmonary embolism treatment at a primary and secondary care centre. In: Balas P, ed. International congress of phlebology. Bologna, Italy: Monduzzi Editore, 1996:141-4.
16. Fareed J, Hoppensteadt D, Jeske W, et al. Low molecular weight heparins: a developmental perspective. Exp Opin Invest Drugs 1997;6(6):705-33.
17. Leong WA, Brown L, Sparling TG. Outpatient deep vein thrombosis resource guide [abstr]. Int Angiol 1997;16(suppl 1-3):83.
18. Leong WA. Outpatient DVT treatment: implementation of an outpatient deep vein thrombosis treatment program using LMWH. Hosp Pharm Pract 1998;6(2):1, 24-31.